Welcome to our dedicated page for ALTERITY THERAPEUTICS SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics Limited reports that 91,392,720 unquoted options with ASX code ATHAAD, exercisable at $0.032 and expiring on 6 January 2026, have lapsed without being exercised or converted. No consideration was paid in connection with this expiry.
Following this change, the company’s issued capital on ASX comprises 10,875,416,329 ordinary fully paid shares (ATH), along with quoted options ATHO (option expiring 31 August 2026) totaling 931,232,089 and ATHOA (option expiring 26 February 2027) totaling 1,222,300,911. Various classes of unquoted options remain on issue, while the ATHAAD class now has zero securities outstanding.